<DOC>
	<DOCNO>NCT00023972</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know gemcitabine effective without exatecan mesylate treat pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness gemcitabine alone gemcitabine exatecan mesylate treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Exatecan Mesylate Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient chemotherapy-naive locally advanced metastatic cancer exocrine pancreas treat exatecan mesylate gemcitabine versus gemcitabine alone . - Compare measure clinical benefit patient treat regimen . - Compare anti-tumor efficacy regimens patient population . - Determine safety profile exatecan mesylate gemcitabine patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord performance status ( 60 % vs 70-80 % vs 90-100 % ) , extent disease ( locally advance vs metastatic ) , prior radiotherapy pancreatic cancer ( yes ) . Patients randomize one two treatment arm . - Arm I : Patients receive exatecan mesylate ( DX-8951f ) IV 30 minute immediately follow gemcitabine IV 30 minute day 1 8 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 30 minute weekly 7 week follow one week rest ( course 1 ) . For subsequent course , patient receive gemcitabine weekly 3 week follow one week rest . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Patients follow monthly . PROJECTED ACCRUAL : Approximately 340 patient ( 170 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm epithelial cancer exocrine pancreas Locally advance ( unresectable ) metastatic disease No islet cell tumor , lymphoma , sarcoma pancreas No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 5 time ULN Albumin least 2.8 g/dL Renal : Creatinine great 1.5 time ULN Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction Other : No serious infection lifethreatening illness unrelated tumor No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No overt psychosis incompetency would preclude study No history positive serology HIV Not pregnant nursing Negative pregnancy test Fertile patient must use contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic anticancer immunotherapy pancreatic cancer No concurrent anticancer immunotherapy biologic therapy Chemotherapy : No prior systemic anticancer chemotherapy pancreatic cancer Prior fluorouracil radiosensitizer allow No prior gemcitabine radiosensitizer No concurrent anticancer chemotherapy Endocrine therapy : Concurrent megestrol appetite stimulation allow Radiotherapy : At least 28 day since prior radiotherapy recover No prior radiotherapy 25 % estimate bone marrow reserve No concurrent anticancer radiotherapy Surgery : At least 28 day since prior major surgery recover No concurrent surgery cancer Other : No prior investigational systemic anticancer therapy pancreatic cancer No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>